Compare · MRK vs VHAQ
MRK vs VHAQ
Side-by-side comparison of Merck & Company Inc. (MRK) and Viveon Health Acquisition Corp. (VHAQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and VHAQ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $276.54B, about 1093.8x VHAQ ($252.8M).
- MRK has hit the wire 9 times in the past 4 weeks while VHAQ has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 0 for VHAQ).
- Company
- Merck & Company Inc.
- Viveon Health Acquisition Corp.
- Price
- $111.84-2.43%
- $11.30+0.00%
- Market cap
- $276.54B
- $252.8M
- 1M return
- -6.32%
- -
- 1Y return
- +34.42%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Viveon Health Acquisition Corp.
Viveon Health Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Norcross, Georgia.
Latest MRK
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
- Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
- FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
- European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
- New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada
- Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
- SEC Form DEFA14A filed by Merck & Company Inc.
- SEC Form DEF 14A filed by Merck & Company Inc.
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
- Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Latest VHAQ
- SEC Form 425 filed by Viveon Health Acquisition Corp.
- SEC Form 8-K filed by Viveon Health Acquisition Corp.
- SEC Form 25-NSE filed by Viveon Health Acquisition Corp.
- SEC Form 10-Q filed by Viveon Health Acquisition Corp.
- SEC Form 425 filed by Viveon Health Acquisition Corp.
- Viveon Health Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success
- SEC Form 425 filed by Viveon Health Acquisition Corp.
- Viveon Health Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Viveon Health Acquisition Corp.